Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 186436, 9 pages
http://dx.doi.org/10.1155/2015/186436
Research Article

The Flavonoid Apigenin Ameliorates Cisplatin-Induced Nephrotoxicity through Reduction of p53 Activation and Promotion of PI3K/Akt Pathway in Human Renal Proximal Tubular Epithelial Cells

1Department of Pathology, College of Korean Medicine, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea
2Department of Pathology, Chonbuk National University Medical School, Research Institute of Clinical Medicine and Institute for Medical Sciences, Jeonju, Jeonbuk 561-756, Republic of Korea
3Department of Microbiology and Immunology, Wonkwang University School of Medicine, Iksan, Jeonbuk 570-749, Republic of Korea
4Department of Neuropsychiatry, College of Korean Medicine, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea
5Research Center of Traditional Korean Medicine, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea

Received 27 February 2015; Accepted 10 May 2015

Academic Editor: Jintanaporn Wattanathorn

Copyright © 2015 Sung Min Ju et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Kelland, “The resurgence of platinum-based cancer chemotherapy,” Nature Reviews Cancer, vol. 7, no. 8, pp. 573–584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Barabas, R. Milner, D. Lurie, and C. Adin, “Cisplatin: a review of toxicities and therapeutic applications,” Veterinary and Comparative Oncology, vol. 6, no. 1, pp. 1–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. H. Hanigan and P. Devarajan, “Cisplatin nephrotoxicity: molecular mechanisms,” Cancer Therapy, vol. 1, pp. 47–61, 2003. View at Google Scholar
  4. S. R. McWhinney, R. M. Goldberg, and H. L. McLeod, “Platinum neurotoxicity pharmacogenetics,” Molecular Cancer Therapeutics, vol. 8, no. 1, pp. 10–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. L. P. Rybak, “Mechanisms of cisplatin ototoxicity and progress in otoprotection,” Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 15, no. 5, pp. 364–369, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. L. X. Cubeddu, “Mechanisms by which cancer chemotherapeutic drugs induce emesis,” Seminars in Oncology, vol. 19, no. 6, pp. 2–13, 1992. View at Google Scholar · View at Scopus
  7. P. E. Kintzel, “Anticancer drug-induced kidney disorders: incidence, prevention and management,” Drug Safety, vol. 24, no. 1, pp. 19–38, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Pabla and Z. Dong, “Cisplatin nephrotoxicity: mechanisms and renoprotective strategies,” Kidney International, vol. 73, no. 9, pp. 994–1007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Jiang, Q. Wei, N. Pabla et al., “Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity,” Biochemical Pharmacology, vol. 73, no. 9, pp. 1499–1510, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. Ju, H. O. Pae, W. S. Kim, D. G. Kang, H. S. Lee, and B. H. Jeon, “Role of reactive oxygen species in p53 activation during cisplatin-induced apoptosis of rat mesangial cells,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 8, pp. 1135–1141, 2014. View at Google Scholar
  11. C. Manach, A. Scalbert, C. Morand, C. Rémésy, and L. Jiménez, “Polyphenols: Food sources and bioavailability,” The American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 727–747, 2004. View at Google Scholar · View at Scopus
  12. Y.-J. Surh, “Cancer chemoprevention with dietary phytochemicals,” Nature Reviews Cancer, vol. 3, no. 10, pp. 768–780, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Arsić, V. Tadić, D. Vlaović et al., “Preparation of novel apigenin-enriched, liposomal and non-liposomal, antiinflammatory topical formulations as substitutes for corticosteroid therapy,” Phytotherapy Research, vol. 25, no. 2, pp. 228–233, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. V. Singh, K. Selvendiran, S. Mumtaz Banu, R. Padmavathi, and D. Sakthisekaran, “Protective role of Apigenin on the status of lipid peroxidation and antioxidant defense against hepatocarcinogenesis in Wistar albino rats,” Phytomedicine, vol. 11, no. 4, pp. 309–314, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. K. Ha, P. Lee, J. A. Park et al., “Apigenin inhibits the production of NO and PGE2 in microglia and inhibits neuronal cell death in a middle cerebral artery occlusion-induced focal ischemia mice model,” Neurochemistry International, vol. 52, no. 4-5, pp. 878–886, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. C. W. Myhrstad, H. Carlsen, O. Nordström, R. Blomhoff, and J. Ø. Moskaug, “Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter,” Free Radical Biology and Medicine, vol. 32, no. 5, pp. 386–393, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Wei, L. Tye, E. Bresnick, and D. F. Birt, “Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice,” Cancer Research, vol. 50, no. 3, pp. 499–502, 1990. View at Google Scholar · View at Scopus
  18. P. Kaur, S. Shukla, and S. Gupta, “Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study,” Carcinogenesis, vol. 29, no. 11, pp. 2210–2217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. E. J. Choi and G.-H. Kim, “Apigenin causes G2/M arrest associated with the modulation of p21Cip1 and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells,” The Journal of Nutritional Biochemistry, vol. 20, no. 4, pp. 285–290, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Das, N. L. Banik, and S. K. Ray, “Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to flavonoids,” International Journal of Cancer, vol. 119, no. 11, pp. 2575–2585, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Gupta, F. Afaq, and H. Mukhtar, “Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells,” Biochemical and Biophysical Research Communications, vol. 287, no. 4, pp. 914–920, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. L.-P. Chan, T.-H. Chou, H.-Y. Ding et al., “Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin,” Biochimica et Biophysica Acta—General Subjects, vol. 1820, no. 7, pp. 1081–1091, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Y. Xu, T. T. Wu, S. H. Zhou et al., “Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 7, pp. 3938–3947, 2014. View at Google Scholar
  24. A. T. M. Vaughan, C. J. Betti, and M. J. Villalobos, “Surviving apoptosis,” Apoptosis, vol. 7, no. 2, pp. 173–177, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Decker and S. Muller, “Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress,” Current Pharmaceutical Biotechnology, vol. 3, no. 3, pp. 275–283, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. S. R. Datta, A. Brunet, and M. E. Greenberg, “Cellular survival: a play in three akts,” Genes & Development, vol. 13, no. 22, pp. 2905–2927, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, and M. D. Waterfield, “Cellular function of phosphoinositide 3-kinase: implications for development, immunity, homeostasis, and cancer,” Annual Review of Cell and Developmental Biology, vol. 17, pp. 615–675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Luo, B. D. Manning, and L. C. Cantley, “Targeting the PI3K-Akt pathway in human cancer: rationale and promise,” Cancer Cell, vol. 4, no. 4, pp. 257–262, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Ogawara, S. Kishishita, T. Obata et al., “Akt enhances Mdm2-mediated ubiquitination and degradation of p53,” The Journal of Biological Chemistry, vol. 277, no. 24, pp. 21843–21850, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Solmaz, A. Adan Gokbulut, B. Cincin et al., “Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells,” Nutrition and Cancer, vol. 66, no. 4, pp. 599–612, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Maggioni, W. Garavello, R. Rigolio, L. Pignataro, R. Gaini, and G. Nicolini, “Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis,” International Journal of Oncology, vol. 43, no. 5, pp. 1675–1682, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Arango, A. Parihar, F. A. Villamena et al., “Apigenin induces DNA damage through the PKCδ-dependent activation of ATM and H2AX causing down-regulation of genes involved in cell cycle control and DNA repair,” Biochemical Pharmacology, vol. 84, no. 12, pp. 1571–1580, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. H.-F. Lu, Y.-J. Chie, M.-S. Yang et al., “Apigenin induces apoptosis in human lung cancer H460 cells through caspase- and mitochondria-dependent pathways,” Human & Experimental Toxicology, vol. 30, no. 8, pp. 1053–1061, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Cheung and J. R. Testa, “Diverse mechanisms of AKT pathway activation in human malignancy,” Current Cancer Drug Targets, vol. 13, no. 3, pp. 234–244, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Honda, H. Tanaka, and H. Yasuda, “Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53,” FEBS Letters, vol. 420, no. 1, pp. 25–27, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. K. Yu, R. K. Geyer, and C. G. Maki, “MDM2-dependent ubiquitination of nuclear and cytoplasmic P53,” Oncogene, vol. 19, no. 51, pp. 5892–5897, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Fraser, B. M. Leung, X. Yan, H. C. Dan, J. Q. Cheng, and B. K. Tsang, “p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells,” Cancer Research, vol. 63, no. 21, pp. 7081–7088, 2003. View at Google Scholar · View at Scopus
  38. M. R. Abedini, E. J. Muller, R. Bergeron, D. A. Gray, and B. K. Tsang, “Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein,” Oncogene, vol. 29, no. 1, pp. 11–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Skladanowski, P. Bozko, M. Sabisz, and A. K. Larsen, “Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy,” Cell Cycle, vol. 6, no. 18, pp. 2268–2275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Zhang, M. Li, X. Zhu, Y. Bai, and C. Yang, “Knockdown of Akt sensitizes osteosarcoma cells to apoptosis induced by cisplatin treatment,” International Journal of Molecular Sciences, vol. 12, no. 5, pp. 2994–3005, 2011. View at Publisher · View at Google Scholar · View at Scopus